LO

LongRiver Investments — Seed & Series A VC Firm

VC

LongRiver Investments is a Seed, Series A venture capital firm investing in AI / ML, Other, SaaS. The firm has 5 portfolio companies in our records.

Portfolio
5 companies on record
Partners
2 listed
AUM
$1B
Stage
Seed, Series A
Sectors
AI / ML, Other, SaaS, Developer Tools
Check size
Not in our records
How to approach: warm intro preferred
Stage

Seed, Series A

AUM

$1.0B

Portfolio

5+ companies

Team

2 partners

Investment Thesis

Investor seen in an AI recruiting software round. That suggests openness to AI-enabled hiring workflows and recruiting infrastructure that reduces manual screening load.

How LongRiver Investments invests

LongRiver Investments is a vc firm. The firm invests at the Seed, Series A stages, with a focus on AI / ML, Other, SaaS, Developer Tools.

LongRiver Investments manages approximately $1B in assets. Our records include 2 funds raised by the firm.

LongRiver Investments has backed 5 companies in our records, including Rona Therapeutics, Sironax, SciBrunch Therapeutics.

Partners & Team

U

Unknown

Partner

AI recruiting
GR

Graham Rhodes

Founder

global equity strategy
value investing
Asia-informed investments

Graham Rhodes founded Longriver Investment Partners in Hong Kong. He manages a global equity strategy for long-term investors and invests in a focused group of public companies. His roots in Asia shape his investment approach, emphasizing value investing and capital-efficient businesses.

Industry Focus

Invests In

AI / ML
Other
SaaS
Developer Tools

Funds

LongRiver Growth Fund II

$350M2021
investing

LongRiver Growth Fund

$200M2019
investing

Portfolio Companies (5)

Other

RO

Rona Therapeutics

Biotech / RNA therapeutics·Series A+

Clinical-stage biotech developing metabolic siRNA pipeline and RNA platform technologies.

SI

Sironax

Biotech·Series B

Biotech focused on treatments for age-related degenerative diseases.

SC

SciBrunch Therapeutics

Biotech / oncology·Angel financing; Pre-A follow-on

Biotech company developing SPR2015, an investigational oral KRAS G12D inhibitor.

PE

PepStar Therapeutics

Biotech / therapeutics·Seed; two follow-on rounds

Peptide therapeutics company advancing oral IL-23R inhibitor programs.

OU

Ouro Medicines

Biotech / immunology·Series A

Clinical-stage biotech developing T-cell engager therapies for autoimmune diseases.

How to pitch LongRiver Investments
  • •Raising at Seed, Series A? You're squarely in their sweet spot.
  • •Lead with your fit in AI / ML, Other, SaaS — the sectors they actively back.
  • •warm intro preferred
  • •Address your outreach to a specific partner, such as Unknown, Partner.
  • •A warm introduction beats a cold email. Get matched and request an intro.

Featured In

Browse More Investors

Fundraising resources

Frequently Asked Questions

See if LongRiver Investments is a match for your startup

Upload your pitch deck to see how well you match with LongRiver Investments and 10,000+ other investors.

Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT

Is this your profile? Request a correction or removal